4D Molecular Therapeutics, Inc. - 8-K Filing
On June 17, 2026, 4D Molecular Therapeutics held its annual stockholder meeting where three proposals were voted on. Stockholders elected Nancy Miller-Rich, John F. Milligan, and Shawn Cline Tomasello to the Board of Directors; ratified PwC as their independent auditor with 99.87% approval (43,900,362 votes); and approved executive compensation advisory vote with 81.95% support (36,065,437 votes). (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $FDMT